Anti-tubercular activity of eleven aromatic and medicinal plants occurring in Colombia
Keywords:
Mycobacterium tuberculosis, tuberculosis, anti-infective agents, plants, medicinal, phytotherapy, Colombia
Abstract
Introduction. Human tuberculosis is a contagious-infectious disease mainly caused by Mycobacterium tuberculosis. Although regimens exist for treating tuberculosis, they are far from ideal. Development of effective strategies for treatment of human tuberculosis has posed a challenge, considering the increase in infections associated with the human immunodeficiency virus and immunocompromised patients. Essential oils -volatile, aromatic oil extracts from plants-have been used in traditional treatment of many diseases; however careful investigation of these oils has not been undertaken with respect to treatments of tuberculosis.Objective. The in vitro antitubercular activity of essential oils from 11 medicinal plants grown in Colombia were assessed for efficacy as new medications (phytomedicines) for treatment of M. tuberculosis H37Rv.
Material and methods. Essential oil extraction and analysis were performed as described Stashenko et al. (2004). Minimal inhibitory concentrations were determined by a colorimetric macrodilution method, following the protocol described by Abate et al. (1998). Isoniazide and rifampin were used as control treatments. Bactericidal and bacteriostatic activity was measured using the method developed by the Clinical and Laboratory Standards Institute consigned in the M26-A protocol.
Results. Essential oils from Achyrocline alata and Swinglea glutinosa were the most active with minimal inhibitory concentrations of 62.5±0.1 and 100±36 μg ml-1, respectively. Carvacrol, thymol, p-cymene, 1,8-cineole, limonene, and β-pinene were the major components ,most often identified in the 11 plant extracts of essential oils. Time-kill curve assays demonstrated the bacteriostatic activity of these essential oils.
Conclusions. The essential oils from A. alata and S. glutinosa plants, and the components identified therein, are candidates as potential phytotherapeutic agents for human tuberculosis control.
Downloads
Download data is not yet available.
References
1. Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption-a review on tuberculosis. Mem Inst Oswaldo Cruz. 2006;101:697-714.
2. Zumla A, Grange J. Tuberculosis. BMJ. 1998; 316: 1962-4.
3. Chang Blanc D, Nunn P. Incentives and disincentives for new anti-tuberculosis drug development. Geneva: World Health Organization; 1999.
4. National Institute of Allergy and Infectious Diseases. NIAID Global Health Research Plan for HIV/AIDS, malaria, and tuberculosis. Bethesda: National Institute of Allergy and Infectious Diseases; 2001.
5. Heinrich M, Gibbons S. Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. J Pharm Pharmacol. 2001;53:425-32.
6. Gautam R, Saklani A, Jachak SM. Indian medicinal plants as a source of antimycobacterial agents. J Ethnopharmacol. 2007;110:200-34.
7. Edris AE. Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: a review. Phytother Res. 2007;21:308-23.
8. Cantrell CL, Franzblau SG, Fischer NH. Anti-myco-bacterial plant terpenoids. Planta Med. 2001;67:685-94.
1. Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption-a review on tuberculosis. Mem Inst Oswaldo Cruz. 2006;101:697-714.
2. Zumla A, Grange J. Tuberculosis. BMJ. 1998; 316: 1962-4.
3. Chang Blanc D, Nunn P. Incentives and disincentives for new anti-tuberculosis drug development. Geneva: World Health Organization; 1999.
4. National Institute of Allergy and Infectious Diseases. NIAID Global Health Research Plan for HIV/AIDS, malaria, and tuberculosis. Bethesda: National Institute of Allergy and Infectious Diseases; 2001.
5. Heinrich M, Gibbons S. Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. J Pharm Pharmacol. 2001;53:425-32.
6. Gautam R, Saklani A, Jachak SM. Indian medicinal plants as a source of antimycobacterial agents. J Ethnopharmacol. 2007;110:200-34.
7. Edris AE. Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: a review. Phytother Res. 2007;21:308-23.
8. Cantrell CL, Franzblau SG, Fischer NH. Anti-myco-bacterial plant terpenoids. Planta Med. 2001;67:685-94.
2. Zumla A, Grange J. Tuberculosis. BMJ. 1998; 316: 1962-4.
3. Chang Blanc D, Nunn P. Incentives and disincentives for new anti-tuberculosis drug development. Geneva: World Health Organization; 1999.
4. National Institute of Allergy and Infectious Diseases. NIAID Global Health Research Plan for HIV/AIDS, malaria, and tuberculosis. Bethesda: National Institute of Allergy and Infectious Diseases; 2001.
5. Heinrich M, Gibbons S. Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. J Pharm Pharmacol. 2001;53:425-32.
6. Gautam R, Saklani A, Jachak SM. Indian medicinal plants as a source of antimycobacterial agents. J Ethnopharmacol. 2007;110:200-34.
7. Edris AE. Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: a review. Phytother Res. 2007;21:308-23.
8. Cantrell CL, Franzblau SG, Fischer NH. Anti-myco-bacterial plant terpenoids. Planta Med. 2001;67:685-94.
1. Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption-a review on tuberculosis. Mem Inst Oswaldo Cruz. 2006;101:697-714.
2. Zumla A, Grange J. Tuberculosis. BMJ. 1998; 316: 1962-4.
3. Chang Blanc D, Nunn P. Incentives and disincentives for new anti-tuberculosis drug development. Geneva: World Health Organization; 1999.
4. National Institute of Allergy and Infectious Diseases. NIAID Global Health Research Plan for HIV/AIDS, malaria, and tuberculosis. Bethesda: National Institute of Allergy and Infectious Diseases; 2001.
5. Heinrich M, Gibbons S. Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. J Pharm Pharmacol. 2001;53:425-32.
6. Gautam R, Saklani A, Jachak SM. Indian medicinal plants as a source of antimycobacterial agents. J Ethnopharmacol. 2007;110:200-34.
7. Edris AE. Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: a review. Phytother Res. 2007;21:308-23.
8. Cantrell CL, Franzblau SG, Fischer NH. Anti-myco-bacterial plant terpenoids. Planta Med. 2001;67:685-94.
How to Cite
1.
Bueno-Sánchez JG, Martínez-Morales JR, Stashenko EE, Ribón W. Anti-tubercular activity of eleven aromatic and medicinal plants occurring in Colombia. Biomed. [Internet]. 2009 Mar. 1 [cited 2025 Apr. 4];29(1):51-60. Available from: https://revistabiomedicaorg.biteca.online/index.php/biomedica/article/view/41
Some similar items:
- Antistio Aníbal Alviz, Rubén Darío Salas, Luis Alberto Franco, Acute diuretic effect of ethanolic and aqueous extracts of Ceratopteris pteridoides (Hook) in normal rats , Biomedica: Vol. 33 No. 1 (2013)
- Julio César Martínez, Claudia Llerena, Yanely Angélica Valbuena, The Importance of investigating Mycobacterium bovis in clinical samples of human origin , Biomedica: Vol. 39 No. Sp. 1 (2019): Suplemento 1, Microbiología médica, mayo
- Nelson José Alvis-Zakzuk, María de los Ángeles Carrasquilla, Verónica Jhajaira Gómez, Jaime Robledo, Nelson Rafael Alvis-Guzmán, José Mauricio Hernández, Diagnostic accuracy of three technologies for the diagnosis of multi-drug resistant tuberculosis , Biomedica: Vol. 37 No. 3 (2017)
- Alvaro Javier Idrovo, Historical, social and epidemiological roots of tuberculosis in Bogotá, Colombia. , Biomedica: Vol. 24 No. 4 (2004)
- Claudia Llerena, Angélica Valbuena, Angie Paola Zabaleta, Mycobacterioses identified in the National Reference Laboratory of Colombia from 2012 to 2016 , Biomedica: Vol. 38 No. Sup. 2 (2018): Suplemento 2, Medicina tropical
- Carlos A. Torres-Duque, Claudia Díaz, Leslie Vargas, Elsa María Serpa, Walter Mosquera, María Consuelo Garzón, Graciela Mejía, Luz Mary García, Liliana Andrea González, Claudia Marcela Castro, Wellman Ribón, Disseminated mycobacteriosis affecting a prosthetic aortic valve: first case of Mycobacterium peregrinum type III reported , Biomedica: Vol. 30 No. 3 (2010)
- John-Leonardo Torres-Castiblanco, Jorge Alberto Carrillo, Daniel Hincapié-Urrego, Adriana Rojas-Villarraga, Tuberculosis in the era of anti-TNF-alpha therapy: Why does the risk still exist? , Biomedica: Vol. 38 No. 1 (2018)
- Claudia Llerena, Angie Zabaleta, Angélica Valbuena, Martha Murcia, Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013 , Biomedica: Vol. 37 No. 1 (2017)
- Adriana Rojas-Villarraga, Carlos Andrés Agudelo, Ricardo Pineda-Tamayo, Alvaro Porras, Gustavo Matute, Juan Manuel Anaya, Tuberculosis in patientes treated with tumor necrosis factor alpha antagonists living in an endemic area. Is the risk worthwhile? , Biomedica: Vol. 27 No. 2 (2007)
- Leandro Galvis, Ángel Y. Sánchez, Leonardo F. Jurado, Martha I. Murcia, Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia , Biomedica: Vol. 38 No. 1 (2018)
Issue
Section
Original articles
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |